Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program

SIMPLE SUMMARY: Leptomeningeal metastases represent an unmet need due to the lack of effective therapy and poor survival. The tyrosine kinase inhibitor, neratinib, has demonstrated promising activity against brain metastases from HER2-positive breast cancer, as reported by the TBCRC and NALA trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellerino, Alessia, Soffietti, Riccardo, Bruno, Francesco, Manna, Roberta, Muscolino, Erminia, Botta, Pierangela, Palmiero, Rosa, Rudà, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909342/
https://www.ncbi.nlm.nih.gov/pubmed/35267501
http://dx.doi.org/10.3390/cancers14051192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909342/
https://www.ncbi.nlm.nih.gov/pubmed/35267501
http://dx.doi.org/10.3390/cancers14051192

Ejemplares similares